{"type":"trials","record":{"id":41738,"source_id":"clinicaltrials-gov","external_id":"NCT06859515","title":"A Long-term Follow up Study of EXG102-031 in Participants With wAMD","brief_summary":"This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Guangzhou Jiayin Biotech Ltd","enrollment":42,"countries":["China"],"start_date":"2025-03-13","completion_date":"2030-12-01","last_update_date":"2025-08-15","source_url":"https://clinicaltrials.gov/study/NCT06859515","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Guangzhou Jiayin Biotech Ltd","interventions":["No intervention, only for observational studies"],"registry_source":"ClinicalTrials.gov","outcome_measures":["long-term safety：the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs). — 4 years","Change from baseline after treatment by EXG102-031：best corrected visual acuity (BCVA) — 4 years","Change from baseline after treatment by EXG102-031：central retinal thickness (CRT) — 4 years","The times of receiving anti-vascular endothelial growth factor (VEGF) therapy after EXG102-031 administrated — 4 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","No intervention, only for observational studies"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06859515","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-03-13 to 2030-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.863Z","intervention":["No intervention, only for observational studies"],"participants":42,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["long-term safety：the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs). — 4 years","Change from baseline after treatment by EXG102-031：best corrected visual acuity (BCVA) — 4 years","Change from baseline after treatment by EXG102-031：central retinal thickness (CRT) — 4 years","The times of receiving anti-vascular endothelial growth factor (VEGF) therapy after EXG102-031 administrated — 4 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41738","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}